Abstract
Introduction: Cytokine storm and oxidative stress play a key role in the pathogenesis of coronavirus disease 2019 (COVID-19). Vitamins C and E are two known antioxidants with possible theoretical beneficial effects in COVID-19 patients.
Objectives: This study aimed to clinically evaluate the effects of the combination of these agents as adjunctive therapy with the standard treatment in the outcome of COVID-19 patients.
Patients and Methods: Hospitalized non-severe COVID-19 patients were randomly divided into two groups of intervention (n=38) and control (n=34) to receive either oral vitamin C 1000 mg daily plus oral vitamin E 400 IU daily in addition to the national standard treatment regimen (hydroxychloroquine) or standard regimen alone, respectively, during the hospitalization period until hospital discharge or ICU admission. The clinical response of patients at the end of treatment (either cure, improvement, or failure), the duration of hospitalization, and the mortality rate were recorded and compared between the groups.
Results: During the study, three patients in the intervention group (7.89%) and five patients in the control group (14.71%) had treatment failure, while all other patients had clinical improvement (P = 0.380). The duration of hospitalization was shorter in the intervention group (7.95 ± 3.18 days) compared to the control group (8.03 ± 2.83 days); however, the difference was not statistically significant (P = 0.821). Furthermore, no patients in both groups died during the study.
Conclusion: The combination of oral vitamins C (1000 mg daily) and E (400 IU daily) has no beneficial effect in COVID-19 patients.
Trial Registration: Registration of trial protocol has been approved in Iranian registry of clinical trials (identifier: IRCT20180425039414N3; https://www.irct.ir/trial/48083, ethical# IR.MUI.MED.REC.1399.047).